Bank of New York Mellon’s Larimar Therapeutics LRMR Stock Holding History

Bank of New York Mellon’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$423K	Buy	138,831 +31,500	+29%	+$125K	﹤0.01%	3821
2026 Q1	$483K	Sell	107,331 -8,597	-7%	-$34.4K	﹤0.01%	3627
2025 Q4	$442K	Buy	115,928 +4,888	+4%	+$19K	﹤0.01%	3680
2025 Q3	$359K	Buy	111,040 +11,151	+11%	+$41.8K	﹤0.01%	3785
2025 Q2	$289K	Sell	99,889 -564	-0.6%	-$1.31K	﹤0.01%	3825
2025 Q1	$216K	Hold	100,453	–	–	﹤0.01%	3856
2024 Q4	$389K	Buy	100,453 +1,823	+2%	+$12K	﹤0.01%	3647
2024 Q3	$646K	Sell	98,630 -36,247	-27%	-$291K	﹤0.01%	3368
2024 Q2	$978K	Buy	134,877 +49,102	+57%	+$376K	﹤0.01%	3216
2024 Q1	$651K	Sell	85,775 -10,989	-11%	-$85.6K	﹤0.01%	3369
2023 Q4	$440K	Sell	96,764 -1,074	-1%	-$3.62K	﹤0.01%	3623
2023 Q3	$386K	Hold	97,838	–	–	﹤0.01%	3683
2023 Q2	$306K	Buy	97,838 +69,021	+240%	+$282K	﹤0.01%	3820
2023 Q1	$131K	Hold	28,817	–	–	﹤0.01%	4025
2022 Q4	$119K	Buy	28,817 +9,844	+52%	+$33.6K	﹤0.01%	4088
2022 Q3	$60K	Hold	18,973	–	–	﹤0.01%	4294
2022 Q2	$37K	Hold	18,973	–	–	﹤0.01%	4408
2022 Q1	$77K	Hold	18,973	–	–	﹤0.01%	4454
2021 Q4	$205K	Hold	18,973	–	–	﹤0.01%	4266
2021 Q3	$219K	Hold	18,973	–	–	﹤0.01%	4177
2021 Q2	$187K	Hold	18,973	–	–	﹤0.01%	4114
2021 Q1	$277K	Buy	+18,973	New	+$345K	﹤0.01%	3941
2019 Q4	–	Sell	-2,094	Closed	-$19K	–	4220
2019 Q3	$19K	Hold	2,094	–	–	﹤0.01%	4184
2019 Q2	$30K	Sell	2,094 -6,682	-76%	-$178K	﹤0.01%	4162
2019 Q1	$288K	Sell	8,776 -4,687	-35%	-$240K	﹤0.01%	3757
2018 Q4	$800K	Buy	13,463 +392	+3%	+$38.7K	﹤0.01%	3232
2018 Q3	$1.83M	Buy	13,071 +2,378	+22%	+$289K	﹤0.01%	2889
2018 Q2	$1.31M	Buy	10,693 +3,349	+46%	+$284K	﹤0.01%	3103
2018 Q1	$656K	Buy	7,344 +46	+0.6%	+$3.9K	﹤0.01%	3443
2017 Q4	$405K	Buy	7,298 +4,245	+139%	+$191K	﹤0.01%	3694
2017 Q3	$129K	Buy	3,053 +48	+2%	+$2K	﹤0.01%	3961
2017 Q2	$126K	Sell	3,005 -5,678	-65%	-$290K	﹤0.01%	3980
2017 Q1	$485K	Buy	8,683 +483	+6%	+$24K	﹤0.01%	3567
2016 Q4	$313K	Buy	8,200 +2,422	+42%	+$98.2K	﹤0.01%	3773
2016 Q3	$230K	Sell	5,778 -1,398	-19%	-$63.5K	﹤0.01%	3854
2016 Q2	$515K	Sell	7,176 -644	-8%	-$50.9K	﹤0.01%	3525
2016 Q1	$627K	Buy	7,820 +1,565	+25%	+$124K	﹤0.01%	3326
2015 Q4	$473K	Sell	6,255 -5	-0.1%	-$803	﹤0.01%	3549
2015 Q3	$2.4M	Sell	6,260 -651	-9%	-$294K	﹤0.01%	2627
2015 Q2	$2.87M	Buy	6,911 +2,819	+69%	+$1.18M	﹤0.01%	2684
2015 Q1	$1.95M	Buy	4,092 +1,533	+60%	+$728K	﹤0.01%	2886
2014 Q4	$947K	Buy	2,559 +1,199	+88%	+$309K	﹤0.01%	3341
2014 Q3	$320K	Buy	+1,360	New	+$308K	﹤0.01%	3766

Other funds holding LRMR

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's LRMR Position: Q2 2026 in Review

Bank of New York Mellon increased its Larimar Therapeutics (LRMR) stake by 29% in Q2 2026, buying an estimated $125K and bringing the position to 138,831 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #3821.

Bank of New York Mellon first reported a position in LRMR in Q3 2014 and has held it in 43 quarters since. The position peaked at $2.87M in Q2 2015. 64 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Bank of New York Mellon held 138,831 shares of Larimar Therapeutics worth $423K as of Q2 2026.
Bank of New York Mellon bought 31,500 Larimar Therapeutics shares in Q2 2026, an estimated $125K.
Larimar Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3821 holding.
Bank of New York Mellon first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 43 quarters since.
Bank of New York Mellon's Larimar Therapeutics position peaked at $2.87M in Q2 2015.
64 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.